Ulrich M, Smith P G, Sampson C, Zuniga M, Centeno M, Garcia V, Manrique X, Salgado A, Convit J
Instituto de Biomedicina, Caracas, Venezuela.
Int J Lepr Other Mycobact Dis. 1991 Sep;59(3):405-15.
In a randomized, double-blind vaccine trial in Venezuela, about 29,000 contacts of leprosy patients have been vaccinated with either a mixture of heat-killed Mycobacterium leprae and BCG or BCG alone, and are being re-surveyed annually to detect new cases of leprosy. All contacts had a serum sample collected at the time of entry into the trial, and 13,020 of these sera have been analyzed for antibodies to phenolic glycolipid-I (PGL-I). Antibody levels have been related to various characteristics of the contacts and to their risk of developing leprosy in the following 4 years. A strong association was found between PGL-I antibody level and the risk of developing leprosy, in spite of possible modification of the incidence rate induced by vaccination. Antibody levels were higher in females than in males, and declined progressively with age. Household contacts had higher levels than did non-household contacts, and levels were higher in individuals from the state in Venezuela which has the highest incidence of the disease. No substantial differences were found in antibody levels between contacts of multibacillary and paucibacillary patients, which may in part reflect the influence of treatment, and there was no clear association with the presence of BCG or lepromin scars or with skin-test responses to PPD and leprosy soluble antigen. The assay of antibodies to PGL-I seems unlikely to provide a sensitive or specific test for infection with M. leprae, and measuring PGL-I antibody levels as a screening procedure to identify those at high risk of developing leprosy is unlikely to be particularly useful in most leprosy control programs. Such assays may be useful for the epidemiological monitoring of changes in the intensity of infection with M. leprae in a community and for the study of carefully defined groups of contacts during some phases of control programs.
在委内瑞拉进行的一项随机双盲疫苗试验中,约29000名麻风病人的接触者接种了灭活麻风杆菌与卡介苗的混合疫苗或单独的卡介苗,并且每年进行重新调查以检测新的麻风病例。所有接触者在进入试验时都采集了血清样本,其中13020份血清已被分析检测针对酚糖脂-I(PGL-I)的抗体。抗体水平已与接触者的各种特征及其在接下来4年中患麻风病的风险相关联。尽管接种疫苗可能改变发病率,但仍发现PGL-I抗体水平与患麻风病的风险之间存在强烈关联。女性的抗体水平高于男性,并且随年龄逐渐下降。家庭接触者的抗体水平高于非家庭接触者,来自委内瑞拉该病发病率最高的州的个体的抗体水平更高。在多菌型和少菌型病人的接触者之间,抗体水平未发现实质性差异,这可能部分反映了治疗的影响,并且与卡介苗或麻风菌素瘢痕的存在以及对结核菌素纯蛋白衍生物(PPD)和麻风病可溶性抗原的皮肤试验反应没有明确关联。检测针对PGL-I的抗体似乎不太可能为麻风杆菌感染提供灵敏或特异的检测方法,并且在大多数麻风病控制项目中,将测量PGL-I抗体水平作为一种筛查程序来识别那些患麻风病高风险人群不太可能特别有用。此类检测方法可能有助于对社区中麻风杆菌感染强度变化进行流行病学监测,以及在控制项目的某些阶段对精心界定的接触者群体进行研究。